Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS
21/10/2026 06:24
BRIEF-Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS Oct 21 (Reuters) - Hansa Biopharma AB HNSA.ST:
SAID ON TUESDAY ANNOUNCES SUBMISSION OF IND APPLICATION TO US FDA FOR HNSA-5487 IN GBS
PLANS TO INITIATE SMALL PHASE 2A SINGLE ASCENDING DOSE (SAD) STUDY OF HNSA-5487 IN PATIENTS WITH GBS, FOLLOWED BY PIVOTAL STUDY
Source text for Workspace: nWkr48qB2l
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS